Martín Broto Javier, Le Cesne Axel, Reichardt Peter
MUsculoSkeletal Tumor Board of Excellence Sevilla (MUSTBE SEVILLA), Virgen del Rocío University Hospital, Sevilla, Spain.
Department of Medical Oncology & Surgery, Institut Gustave Roussy, Villejuif, France.
Future Oncol. 2017 Jan;13(1s):23-31. doi: 10.2217/fon-2016-0500.
While surgical resection (±radiotherapy) is standard treatment for localized soft tissue sarcomas (STS), chemotherapy is the mainstay for managing locally advanced and metastatic disease. Expanding knowledge of the biologies and sensitivities of STS histotypes, in conjunction with results from a growing collection of retrospective reviews and prospective randomized studies, point to the importance of treating in consideration of histological subtype. Doxorubicin ± ifosfamide continues to be standard first-line therapy for most STS subtypes. Main options for second- or later-line therapy include trabectedin, dacarbazine, gemcitabine combinations, pazopanib and, most recently, eribulin. Using illustrative case studies, treatment options are reviewed for three of the more common STS subtypes - uterine leiomyosarcoma, liposarcoma and synovial sarcoma - with a focus on use of trabectedin.
虽然手术切除（±放疗）是局限性软组织肉瘤（STS）的标准治疗方法，但化疗是治疗局部晚期和转移性疾病的主要手段。随着对STS组织学类型的生物学特性和敏感性的了解不断增加，再结合越来越多的回顾性综述和前瞻性随机研究结果，表明考虑组织学亚型进行治疗非常重要。多柔比星±异环磷酰胺仍然是大多数STS亚型的标准一线治疗方案。二线或后续治疗的主要选择包括曲贝替定、达卡巴嗪、吉西他滨联合用药、帕唑帕尼，以及最近的艾瑞布林。通过实例研究，对三种较常见的STS亚型——子宫平滑肌肉瘤、脂肪肉瘤和滑膜肉瘤的治疗选择进行了综述，重点是曲贝替定的使用。
